PTC Therapeutics PTCT Business Segments — Interest Expense Nonoperating
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's business segments — interest expense nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's business segments — interest expense nonoperating?
- PTC Therapeutics (PTCT) reported business segments — interest expense nonoperating of $67.02M in Q1 2026.
- How has PTC Therapeutics's business segments — interest expense nonoperating changed year-over-year?
- PTC Therapeutics's business segments — interest expense nonoperating increased by 30.5% year-over-year, from $51.34M to $67.02M.
- What is the long-term trend for PTC Therapeutics's business segments — interest expense nonoperating?
- Over 2 years (2023 to 2025), PTC Therapeutics's business segments — interest expense nonoperating has grown at a 26.0% compound annual growth rate (CAGR), from $142.51M to $226.31M.
- What does business segments — interest expense nonoperating mean?
- This metric represents the costs incurred by the Life Science segment related to debt obligations and financing activities that are not part of core operating expenses. It reflects the financial burden of the segment's capital structure and debt servicing requirements. Monitoring this helps investors assess the segment's financial leverage and the impact of interest-bearing liabilities on its overall profitability.